dolutegravir + daclatasvir

Dolutegravir + daclatasvir is a combination of two approved small molecule antivirals intended for the coadministration in patients co-infected with HIV-1 and hepatitis C virus (HCV). **Dolutegravir** is an integrase strand transfer inhibitor that prevents HIV-1 genome integration by binding the active site of HIV-1 integrase and blocking strand transfer, essential for viral replication. **Daclatasvir** is a direct-acting antiviral agent against HCV that inhibits the nonstructural viral phosphoprotein NS5A, disrupting RNA replication and virion assembly. Each drug has distinct mechanisms and targets, with dolutegravir primarily indicated for HIV-1 and daclatasvir primarily indicated for chronic HCV, most often genotypes 1 and 3. Clinical studies demonstrate that coadministration does not require dose adjustment, as no clinically significant pharmacokinetic interaction occurs and the combination is well tolerated[1][2][3]. Dolutegravir is developed by ViiV Healthcare and daclatasvir by Bristol Myers Squibb.

Other names

DTG + DCV